// App-Quantinova.ai

1369 : Health‐related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)

Researchers

Presenter

  • Arndt Voaei

Principal Investigators

  • Shukui Qin

  • Masatoshi Kudo

  • Stacie Hudgens

  • Tatsuya Yamashita

  • Jung-Hwan Yoon

  • Laetitia Fartoux

  • Krzysztof. Simon

  • Carlos L. Lpez

  • Max Sung

  • Corina E. Dutcus

  • Silvija Kraljevic

  • Toshiyuki Tamai

  • Nathan Grunow

  • Genevieve Meier

  • Valeriy Breder

Medical Centers

  • Hannover Medical School, Hannover, Germany

  • Nanjing Bayi Hospital, Nanjing, China

  • Niigata University School of Medicine, Niigata, Japan

  • Clinical Outcomes Solutions, Tucson, AZ

  • Kanazawa University, Kanazawa, Japan

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Hospital Saint Antoine, Paris, France

  • Centrum Badan Klinicznych, Wroclaw, Poland,

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Tisch Cancer Institute at Mount Sinai, New York, NY

  • Eisai Inc, Woodcliff Lake, NJ

  • Eisai Ltd., Hatfield, United Kingdom

  • Russian Cancer Scientific Centre, Moscow, Russian Federation

Locations

  • Germany

  • China

  • Japan

  • United States

  • Republic of South Korea

  • France

  • Poland

  • Spain

  • United Kingdom

  • Russia

Companies

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Lenvatinib

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved